Image-guided reentry

See the path.
Control the direction.

TruVue is developing an intravascular ultrasound guided platform designed to bring real-time visualization and directional precision to complex coronary and peripheral interventions.

Explore the technology Partner with TruVue

Founded in Detroit, Michigan by physicians who perform complex CTO intervention. U.S. Patent No. 11,779,362 issued 2023.

TRUE LUMEN CROSS-SECTION VESSEL WALL DEVICE

Stylized illustration. Not an ultrasound image; not to scale.

The challenge

Reentry is a precision problem.

In chronic total occlusion procedures, getting around the blockage is only part of the job. The operator still has to find the true lumen and steer a guidewire into it, through tissue, while protecting the structures around it.

Real angiographic frame from a chronic total occlusion case. A guidewire follows the vessel course in a flat grayscale projection.
Angiography
A real frame from a CTO case: the wire follows the vessel course, yet sits in the subintimal space. The flat projection cannot show which lumen it is in.
Integrated wire exit and Ultrasound View
The sectional view resolves the true lumen, the subintimal space, and the device, so the exit can be aimed at the target.

Limited spatial information

The 2D fluoroscopy cannot show the vessel wall, true lumen, and wire relationships accurately.

Directional uncertainty

Reentry does require precise control of where the guidewire exits the device, and in what direction.

Technical complexity

Complex CTO techniques are difficult to reproduce, which limits broader adoption beyond highly experienced operators.

The TruVue concept

Visualization and direction, in one platform.

TruVue combines intravascular ultrasound imaging with a directionally aligned guidewire exit, so the operator can see the target and send the wire toward it in the same view.

TRUE LUMEN CROSS-SECTION VESSEL WALL DEVICE STEP 01: SEE STEP 02: REENTRY POINT STEP 03: CROSS

Stylized illustration. Not an ultrasound image; not to scale.

01

See

Scan vessel architecture and the relationship between device, vessel wall, and target lumen.

02

Determine Best Reentry Point

Biggest lumen, least calcium.

03

Cross

Advance reentry wire with confidence.

In motion

Watch the concept work.

The reentry video and M-mode display show the intended workflow: identify the true lumen and best segment for entry, and advance the guidewire toward the target.

Reentry video
Watch the film0:32
IVUS-guided true-lumen reentryIdentify the true lumen on ultrasound, orient the directional pathway, and advance the guidewire toward the intended target.
M-mode display
Watch the film0:47
Targeted reentry in M-modeA second view of the concept, highlighting device orientation and guidewire advancement toward the true-lumen target.
IVUS-guided true-lumen reentry
Targeted reentry in M-mode

Conceptual and demonstration films for educational and corporate communication purposes. Investigational technology; not available for sale.

Designed for control

Turn a two-dimensional problem into an image-guided decision.

The TruVue platform is designed to give the operator sectional vessel information at the point where directional wire control matters most.

Predictable. Reproducible. Teachable.

Side-looking IVUS

Designed to visualize local vessel architecture in real time.

Aligned guidewire exit

Designed to make wire direction intuitive and target-oriented.

Platform applications

Coronary and peripheral CTO reentry, proximal cap puncture, and challenging branch access.

“Our goal is simple: give physicians better information and better directional control at one of the most technically demanding moments in complex revascularization.”

Khaldoon Alaswad, MD
Co-founder, TruVue
Leadership

Clinical insight meets device engineering.

Portrait of Khaldoon Alaswad, MD
Co-founder

Khaldoon Alaswad, MD

Interventional cardiologist and physician leader with extensive experience in complex coronary intervention and chronic total occlusion PCI. Dr. Alaswad is an inventor on TruVue’s image-guided reentry intellectual property.

Portrait of Tim A. Fischell, MD
Co-founder

Tim A. Fischell, MD

Physician innovator and cardiovascular device developer with a long record of translating interventional concepts into practical catheter-based technologies.

Portrait of Matt Olson
Acting Vice President of Engineering

Matt Olson

Medical device engineer with over thirty years in the industry, including R&D and operations leadership at Bridgepoint Medical and TERAMed. Inventor on 22 medical device patents.

Advisory board

Emmanouil (Manos) Brilakis, MD, PhD
Director, Center for Complex Coronary Interventions, Minneapolis Heart Institute
J. Aaron Grantham, MD, FSCAI
Interventional Cardiologist, Saint Luke’s Mid America Heart Institute

Khaldoon Alaswad, MD, FACC, FSCAI

Co-founder, TruVue

Practicing physician in Detroit, Michigan. Clinical Assistant Professor of Medicine, Wayne State University, School of Medicine. Clinical Associate Professor of Medicine, Michigan State University. Director, Cardiac Catheterization Laboratory, Edith and Benson Ford Heart and Vascular Institute, Henry Ford Hospital, Henry Ford Health System, Detroit, Michigan.

A nationally and internationally renowned physician with more than 200 peer-reviewed published papers and book chapters. A regular speaker at national and international medical conferences, giving more than 300 lectures in the US, Europe, Africa, and Asia.

His expertise is focused on complex coronary interventions, mechanical circulatory support, and chronic total percutaneous coronary interventions (CTO PCI). Established and leads the world’s most advanced CTO PCI program at Henry Ford Hospital (HFH). Performs over 200 CTO PCI procedures yearly, which is considered one of the top volumes nationally and internationally. HFH’s CTO PCI success rate is above 92%, with unparalleled safety track record.

Established the CHIP/CTO PCI fellowship at Henry Ford Hospital. National and international proctor to hundreds of interventional cardiologists in CTO PCI in China, the Middle East, Europe, and most states in the US.

Has multiple patents in mechanical circulatory support and CTO PCI, coinvented the TruVue device in partnership with Dr. Tim Fischell to make CTO PCI more successful, safer, and teachable to busy interventional cardiologists.

Tim A. Fischell, MD, FACC, MSCAI, FNAI

Co-founder, TruVue

Dr. Fischell is Professor of Medicine at Michigan State University, Clinical Professor of Medicine at Western Michigan University and Medical Director of the Department of Cardiovascular Research as well as Director of the Interventional Cardiology Fellowship Program at the Borgess Heart Institute/MSU in Kalamazoo, Michigan. He also has an active practice as an interventional cardiologist at the Ascension-Borgess Heart Institute in Kalamazoo.

After receiving his medical degree from Cornell University Medical Center in New York City, Dr. Fischell completed an internship and residency in internal medicine at Massachusetts General Hospital/Harvard University in Boston, and completed his interventional cardiology fellowship at Stanford University Medical Center in Palo Alto, California. He was on the faculty at Stanford for five years, and then Director of the cardiac cath labs and interventional cardiology at Vanderbilt University from 1992-1996.

Dr. Fischell has presented more than 200 papers in the United States and abroad. He has authored more than 140 publications in peer-reviewed journals and more than 27 book chapters. He is a member of the editorial board of Cardiovascular Revascularization Medicine, Journal of Invasive Cardiology, and the Journal of Interventional Cardiology.

Dr. Fischell is the inventor or co-inventor of more than 120 patented medical devices. With his father and brother, he has invented the radioisotope stent, pioneering stent designs including the stents for Cordis/Johnson and Johnson, stent delivery systems, an implantable heart attack detection system, the Ostial Pro stent positioning system, a novel renal denervation device (Peregrine), CrossFast guide extension system, and many other medical devices.

He has received numerous awards and honors, including the Thorax Center Andreas Gruntzig Award for Inventor of the Year in 1997, Main Street Medical Award, 2013, Innovation Award at CRT, 2015, Master of Society of Cardiac Angiography and Interventions, and others.

Matt Olson, BS, Mechanical Engineering

Acting Vice President of Engineering, TruVue

Matt has over thirty years of experience in the medical device industry, with seventeen of those years in leadership roles at successful emerging technology companies. He has held roles in R&D, Operations, Manufacturing, and Clinical Training across the span of his career.

He was the Vice President of Engineering and Operations at NexGen Medical Systems from 2017 to 2019. He was the Vice President of Research and Development at Bridgepoint Medical when it was acquired by Boston Scientific and Medtronic in 2012, and he was the Director of Operations at TERAMed when it was acquired by Johnson & Johnson in 2001. Additionally, he has held management positions at American Medical Systems (AMS) and Boston Scientific.

Most recently, he has provided engineering and management consulting and contract services to several startup medical device companies. He currently is listed as an inventor on 22 medical device patents and holds a Bachelor of Science degree in Mechanical Engineering from North Dakota State University.

Interested in clinical collaboration, strategic partnership, or investment?

We welcome conversations with investigators, strategics, and investors working on complex cardiovascular intervention. Write to us any time at kalaswad@truvueinc.com.

Email kalaswad@truvueinc.com